BXQ-350 is under clinical development by Bexion Pharmaceuticals and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BXQ-350’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BXQ-350 is under development for the treatment of cancers including glioblastoma, lung squamous cell carcinoma, malignant glioma, pancreatic cancer, prostate cancer, ependymoma, pediatric diffuse intrinsic pontine glioma, diffuse midline glioma (DMG) and other solid tumors and unspecified central nervous system disorders, lysosomal storage disorder and unspecified viral infections. The drug candidate is administered through intravenous injection. The drug candidate is developed based on Dubbed SapC-DOPS technology. BXQ-350 is a nanovesicle formulation of synthetically produced, human lysosomal protein saposin C (sphingolipid activator protein, or SapC, 80 aa) and the phospholipid dioleoylphosphatidylserine (DOPS). BXQ-350 targets phosphatidylserine (PS) lipids.
It was also under development for the treatment of malignant peripheral nerve sheath tumor, head and neck cancer, neuroblastoma, recurrent solid tumors, brain tumor, breast cancer, pineoblasotoma, osteosarcoma.
Bexion Pharmaceuticals overview
Bexion Pharmaceuticals is a healthcare products and services provider that develops therapies. The company primarily focused in discovery and clinical development of life-changing oncology treatments. The company develops and commercializes drugs for the treatment of cancer. Bexion Pharmaceuticals phospholipid dioleoylphosphatidylserine is used for targeting and treating cancers such as glioblastoma multiforme. The company’s BXQ-350 is a formulation of a synthetically produced human lysosomal protein. It operates through cancer institute for the research on BXQ-350 nanovesicle for the treatment of cancer. Bexion Pharmaceuticals is headquartered in Covington, Kentucky, the US.
For a complete picture of BXQ-350’s drug-specific PTSR and LoA scores, buy the report here.